Fredag 29 November | 17:44:12 Europe / Stockholm

Prenumeration

Kalender

Tid*
2025-02-13 08:00 Bokslutskommuniké 2024
2024-11-07 - Kvartalsrapport 2024-Q3
2024-08-22 - Kvartalsrapport 2024-Q2
2024-05-15 - X-dag ordinarie utdelning ACARIX 0.00 SEK
2024-05-14 - Årsstämma
2024-05-14 - Kvartalsrapport 2024-Q1
2024-02-21 - Extra Bolagsstämma 2024
2024-02-15 - Bokslutskommuniké 2023
2023-11-09 - Kvartalsrapport 2023-Q3
2023-09-28 - Extra Bolagsstämma 2023
2023-08-31 - Kvartalsrapport 2023-Q2
2023-05-12 - X-dag ordinarie utdelning ACARIX 0.00 SEK
2023-05-11 - Årsstämma
2023-05-11 - Kvartalsrapport 2023-Q1
2023-02-16 - Bokslutskommuniké 2022
2022-12-09 - Extra Bolagsstämma 2022
2022-11-16 - Kvartalsrapport 2022-Q3
2022-08-25 - Kvartalsrapport 2022-Q2
2022-05-12 - X-dag ordinarie utdelning ACARIX 0.00 SEK
2022-05-11 - Årsstämma
2022-05-11 - Kvartalsrapport 2022-Q1
2022-02-17 - Bokslutskommuniké 2021
2021-11-23 - Extra Bolagsstämma 2021
2021-11-11 - Kvartalsrapport 2021-Q3
2021-08-19 - Kvartalsrapport 2021-Q2
2021-05-12 - X-dag ordinarie utdelning ACARIX 0.00 SEK
2021-05-11 - Årsstämma
2021-05-11 - Kvartalsrapport 2021-Q1
2021-02-18 - Bokslutskommuniké 2020
2020-11-12 - Kvartalsrapport 2020-Q3
2020-08-20 - Kvartalsrapport 2020-Q2
2020-08-11 - Extra Bolagsstämma 2020
2020-05-15 - X-dag ordinarie utdelning ACARIX 0.00 SEK
2020-05-14 - Årsstämma
2020-05-14 - Kvartalsrapport 2020-Q1
2020-02-20 - Bokslutskommuniké 2019
2019-11-14 - Kvartalsrapport 2019-Q3
2019-08-21 - Kvartalsrapport 2019-Q2
2019-08-16 - Extra Bolagsstämma 2019
2019-05-17 - X-dag ordinarie utdelning ACARIX 0.00 SEK
2019-05-16 - Årsstämma
2019-05-16 - Kvartalsrapport 2019-Q1
2019-02-20 - Bokslutskommuniké 2018
2018-11-14 - Kvartalsrapport 2018-Q3
2018-08-21 - Kvartalsrapport 2018-Q2
2018-05-24 - X-dag ordinarie utdelning ACARIX 0.00 SEK
2018-05-23 - Årsstämma
2018-05-23 - Kvartalsrapport 2018-Q1
2018-02-26 - Bokslutskommuniké 2017
2017-11-14 - Kvartalsrapport 2017-Q3
2017-08-24 - Kvartalsrapport 2017-Q2
2017-05-26 - X-dag ordinarie utdelning ACARIX 0.00 SEK
2017-05-24 - Årsstämma
2017-05-24 - Kvartalsrapport 2017-Q1
2017-02-23 - Bokslutskommuniké 2016

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Acarix är ett diagnostikbolag. Bolaget har utvecklat en teknologi som möjliggör identifiering av kranskärlssjukdomar. Bolagets produkt är ett icke-invasivt test som sätts med en lapp på patienten för att analysera ljud från hjärtat. Idag innehas verksamhet främst inom den nordiska marknaden. Bolaget grundades under 2009 som en avknoppning från Coloplast. Huvudkontoret ligger i Malmö.
2024-02-02 10:10:00

Acarix, a leader in advanced acoustic and algorithm based cardiac diagnostic devices today announces that its CADScor System has been added to the US Federal Supply Schedule. The nationwide contract simplifies purchasing and enables Veterans Affairs Healthcare (VA) and other federal agencies to more efficiently source the Acarix CADScor System.

The Federal Supply Schedule (FSS), managed by the General Services Administration, is a program designed to facilitate and streamline the procurement process for the US federal government and its agencies, including the VA Healthcare Systems. This program simplifies purchasing by providing federal agencies with a list of approved vendors and products, ensuring an efficient and reliable acquisition process.

"Capturing a place on the Federal Supply Schedule is not just an opportunity for positive recognition; it's a valuable endorsement that elevates Acarix's credibility and standing within US federal agencies” stated Aamir Mahmood, Acarix CEO. He continues "While individual VA Healthcare Systems will still need to undergo their normal approval processes to purchase the CADScor System within their approved budgets, the Federal Supply Schedule significantly streamlines the contractual purchasing procedure. This not only facilitates smoother engagements within the VA sector for Acarix but also serves as a key that unlocks additional government contracting opportunities to further solidify our position with CADScor System in the US market," stated Aamir Mahmood, Acarix CEO.

"Securing a position on the Federal Supply Schedule is a significant achievement and reflects the government's confidence in both the value of this new medical technology and Force Medical Solutions' capability to deliver it nationally. This contract award streamlines current processes and adds key validation, undoubtedly opening doors for business at VA Hospitals across the country," stated Norm Cross, Force Medical Solutions CEO and Acarix's SDVOSB Government Distribution partner. "Being on the Federal Supply Schedule offers vendors like us an efficient avenue to provide novel medical technologies to the VA Healthcare System. This facilitates easier procurement for federal agencies and expands opportunities for Force Medical Solutions to contribute effectively in ruling out significant coronary artery disease for our veterans experiencing stable chest pain. "

The Federal Supply Schedule stands as a mechanism benefiting both government agencies and commercial vendors. This structure streamlines the acquisition of diverse products and services, ensuring adherence to stringent federal acquisition standards.